EP1100521A4 - C7f2-a novel potassium channel beta-subunit - Google Patents
C7f2-a novel potassium channel beta-subunitInfo
- Publication number
- EP1100521A4 EP1100521A4 EP99937511A EP99937511A EP1100521A4 EP 1100521 A4 EP1100521 A4 EP 1100521A4 EP 99937511 A EP99937511 A EP 99937511A EP 99937511 A EP99937511 A EP 99937511A EP 1100521 A4 EP1100521 A4 EP 1100521A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- subunit
- potassium channel
- channel beta
- novel potassium
- novel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12302098A | 1998-07-27 | 1998-07-27 | |
PCT/US1999/016949 WO2000006183A1 (en) | 1998-07-27 | 1999-07-27 | C7F2-A NOVEL POTASSIUM CHANNEL β-SUBUNIT |
US123020 | 2002-04-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1100521A1 EP1100521A1 (en) | 2001-05-23 |
EP1100521A4 true EP1100521A4 (en) | 2002-10-09 |
Family
ID=22406262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99937511A Withdrawn EP1100521A4 (en) | 1998-07-27 | 1999-07-27 | C7f2-a novel potassium channel beta-subunit |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1100521A4 (en) |
JP (1) | JP2002524030A (en) |
AU (1) | AU5232799A (en) |
CA (1) | CA2335643A1 (en) |
MX (1) | MXPA01000952A (en) |
WO (1) | WO2000006183A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000050444A1 (en) * | 1999-02-23 | 2000-08-31 | Icagen, Inc. | Bk beta subunits of slo family potassium channels |
CN1329069A (en) * | 2000-06-21 | 2002-01-02 | 上海博德基因开发有限公司 | A novel polypeptide-human PLP protein 39 and polynucleotide for coding this polypeptide |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999042575A2 (en) * | 1998-02-17 | 1999-08-26 | Sanofi-Synthelabo | Calcium-activated potassium channel beta subunit gene and protein |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8951191A (en) * | 1990-10-29 | 1992-05-26 | Dekalb Plant Genetics | Isolation of biological materials using magnetic particles |
US5637470A (en) * | 1994-05-13 | 1997-06-10 | Merck & Co., Inc. | Screening array using cells expressing recombinant α and β subunits of the mammalian large-conductance (maxi-K) potassium channel |
-
1999
- 1999-07-27 AU AU52327/99A patent/AU5232799A/en not_active Abandoned
- 1999-07-27 CA CA002335643A patent/CA2335643A1/en not_active Abandoned
- 1999-07-27 WO PCT/US1999/016949 patent/WO2000006183A1/en not_active Application Discontinuation
- 1999-07-27 JP JP2000562037A patent/JP2002524030A/en active Pending
- 1999-07-27 EP EP99937511A patent/EP1100521A4/en not_active Withdrawn
- 1999-07-27 MX MXPA01000952A patent/MXPA01000952A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999042575A2 (en) * | 1998-02-17 | 1999-08-26 | Sanofi-Synthelabo | Calcium-activated potassium channel beta subunit gene and protein |
Non-Patent Citations (5)
Title |
---|
DATABASE GENBANK [online] 28 September 1994 (1994-09-28), XP002208382, Database accession no. L26101 * |
KNAUS HANS-GUNTHER ET AL: "Primary sequence and immunological characterization of beta-subunit of high conductance Ca-2+-activated K+ channel from smooth muscle.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 25, 1994, pages 17274 - 17278, XP002208380, ISSN: 0021-9258 * |
MAJUMDER KUMUD ET AL: "Molecular cloning and functional expression of a novel potassium channel beta-subunit from human atrium.", FEBS LETTERS, vol. 361, no. 1, 1995, pages 13 - 16, XP002208381, ISSN: 0014-5793 * |
OBERST CORINNA ET AL: "Suppression in transformed avian fibroblasts of a gene (CO6) encoding a membrane protein related to mammalian potassium channel regulatory subunits.", ONCOGENE, vol. 14, no. 9, 1997, pages 1109 - 1116, XP001088992, ISSN: 0950-9232 * |
See also references of WO0006183A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2000006183A1 (en) | 2000-02-10 |
EP1100521A1 (en) | 2001-05-23 |
JP2002524030A (en) | 2002-08-06 |
AU5232799A (en) | 2000-02-21 |
CA2335643A1 (en) | 2000-02-10 |
MXPA01000952A (en) | 2002-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0101269A3 (en) | Potassium channel inhibitors | |
EP1133474A4 (en) | 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators | |
PL341642A1 (en) | Novel macrolydes | |
AU133942S (en) | Channel member | |
AU4411399A (en) | Potassium channel inhibitors | |
EP1056765A4 (en) | Human potassium channel genes | |
EP1068213A4 (en) | Novel aminoorganofunctionalsiloxanes | |
ZA9811591B (en) | Potassium channel openers | |
GB9612829D0 (en) | Potassium channel blockers | |
SG72958A1 (en) | Band | |
GB2337931B (en) | Sunshade | |
GB2334853B (en) | Engineering operations channel provision | |
EP1100521A4 (en) | C7f2-a novel potassium channel beta-subunit | |
IL143148A0 (en) | Potassium channel interactors and uses therefor | |
EP1097166A4 (en) | Potassium channel polypeptide and polynucleotide compositions | |
AU2532299A (en) | Potassium channel polypeptide | |
AU3835499A (en) | Potassium channel subunit | |
EP1077705A4 (en) | Potassium channel agonists | |
EP1347049A4 (en) | Novel potassium channel | |
EP1347050A4 (en) | Novel potassium channel | |
SI1040097T1 (en) | Potassium channel openers | |
EP1121379A4 (en) | MAMMALIAN elk POTASSIUM CHANNEL GENES | |
TW351069U (en) | Novel helmet | |
CA83807S (en) | Chisel | |
ZA976640B (en) | Potassium channel inhibitors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010201 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20020823 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20050808 |